The last quarter of 2020 saw the beginning of the roll-out of coronavirus vaccines in the quickest countries off the mark and saw some big biopharma M&A deals, 18 January 2021
At least one aspect of 2020 will be the same as any other year – pharma companies will end it with the traditional major data dump at the American Society of He 26 November 2020
Two weeks after Americans voted in the presidential election, the losing candidate, Donald Trump, remains in denial over the outcome of the poll. 18 November 2020
With an essential role in the health and well-being of societies, the pharmaceutical industry has long attracted robust levels of capital, matching the high cos 28 October 2020
If any single chart could tell the tale of Takeda’s global pharmaceutical ambitions, it would be one showing change in annual revenues. 27 October 2020
Another coronavirus quarter has come and gone, with pharma companies either thriving, doing their best to mitigate the negative impacts or somewhere in between. 19 October 2020
Despite a range of online resources to facilitate interactions between attendees, there clearly won’t be the same opportunities for networking at this year’s an 15 September 2020
The annual congress of the European Society of Medical Oncology (ESMO) will look a lot different this time, but that does not mean the data will be any less imp 4 September 2020
Given the lack of Phase III data, it is not surprising that some international media reports reacted with scepticism to Russia’s approval of the so-called Sputn 20 August 2020
The High Court has handed down its second judgment in Merck KGaA v Merck Sharp & Dohme, the long-running dispute between two pharmaceutical companies regarding 3 August 2020
Chinese publication Science and Technology Daily has analyzed the progress of the AstraZeneca and University of Oxford coronavirus vaccine alongside a competito 24 July 2020
Reaching into every part of professional and personal life, the coronavirus pandemic has turned the world on its head, making old certainties seem fragile while 1 May 2020
Like many companies announcing projects targeting COVID-19, German immunotherapeutics specialist BioNTech experienced a share price fillip when it announced pla 24 April 2020
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.